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Abstract 
Beveridgean and bismarckian health models have been presented as best striking the balance 
between equity of access, efficiency and cost control. Therefore, it would be interesting to see how these 
compare in a series of health indicators. 
Although some authors have already addressed this issue, this work uses the most recent (and 
complete) data from the Organisation for Economic Co-operation and Development (OECD) databases 
made available in the context of the "Health at a Glance 2015 – OECD Indicators" report. The results are 
then adjusted to the economic capacity of the populations (Gross Domestic Product (GDP) per capita). In 
addition, this paper attempts to understand whether economic capacity per se is capable of influencing 
health outcomes, and how the richest and poorest countries compare, within each model. 
The results of this study show that the differences found in a simple analysis between health 
systems are less than ever. Among these, medical productivity and ease of access to health care are 
favourable to non-Beveridge models. However, it is also in these models that the poorest countries have 
worse results, so they will be able to more easily amortize the social differences compared to the richest 
countries in the beveridgean model. Finally, the main determinants of health outcomes are GDP per capita 
and, consequently, health expenditure per capita, although there seems to be a point (somewhere between 
the second and third quartiles of GDP per capita) where economic capacity ceases to play such a 
preponderant role in health outcomes. 
Introduction 
The universal access to quality health care has been, over the last decades, a key issue within the 
health policy debate in several countries. Thus, it is becoming increasingly evident the converging 
towards a system that tries to guarantee this universality. 
 In fact, except minor adjustments by each country, it is possible nowadays to try to categorize a 
given health system within four basic models: Bismarck, Beveridge, Private Insurance and out-of-pocket. 
The latter is mostly seen in the poorest countries, like India, Pakistan or Cambodia where, in the absence 
of a health payment system, there is an almost total dependence on charitable services or, more often, on 
the exclusive user’s payment (out-of-pocket payment) (Lee and Mir 2014).  
The Private Insurance has been classically associated, in its pure form, to the United States (US), 
where historically there is always been a dominance of the private health insurances, except for the social 
contribution through the Medicare and Medicaid programs, which covered a tiny portion of the 
population in the earliest stages (Lameire et al. 1999); in 2014, about 66% of the residents in the country 
were covered by a private voluntary health insurance, while the public programmes encompassed about 
36,5% of the US residents –  Medicare accounted for 16%, Medicaid for about 19,5% and the military 
health care insurance was responsible for 4,5% (some residents met criteria for more than one insurance 
scheme). About 33 million people in the US had no health cover at all, which represents 10,6% of the 
population. Thereat, the Affordable Care Act program had been enacted in 2010, which aimed to protect 
the less privileged parcel of the population, and has been accomplishing its goal since its creation, with 
2015 projections pointing to a reduction of about 24 million people not covered by health insurance in 
2018 (E. Mossialos January 2016), although this will depend on political choices. 
The beveridgean model is based on the idea of an universal free access to health care, envisioned 
several centuries ago, and probably first described, in a more organized way, by John Bellers, still in the 
eighteenth century (Moore 2008). Just over two centuries later does it lastly takes shape in the United 
Kingdom (UK), by the Act of 1946 and based on the recommendations of the Sir William Beveridge’s 
report (Beveridge 2000). This model resorts on tax collection to support a public scheme that includes 
health services intended to be universal, being these provided by centrally managed entities; in the 
Beveridge model there is a pyramidal hierarchical organization, where primary health care stand at the 
bottom and the highly specialized hospitals at the top; the access to the latter ones is generally dependent 
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on the referral by a general practitioner (GP) (gatekeeping system), following a strict geographic 
subdivision (Bevan et al. 2010; van der Zee and Kroneman 2007).  
On the other hand, the bismarckian model was born in Germany in 1883, coined by Otto von 
Bismarck with its Sickness Insurance Law, which makes this country the first to have a national social 
health insurance system (Ziller et al. 2015). It differs from the beveridgean model in that it is more 
pluralist, with multiple insurers, and the providers are private. There is no gatekeeping system, allowing 
direct access to the hospital specialities, being these parallel to the primary health care (there is no 
pyramidal hierarchy); hence, there are no geographical access restrictions too (Bevan et al. 2010; van der 
Zee and Kroneman 2007). 
Since the implementation of a health model in Germany, many countries have been following the 
example: France has completed the Western Europe coverage in 1928; in Russia, a National Health 
Service was created in 1937, fed by general revenues and consequence of the Russian Revolution of 
1917; in New Zealand, the health coverage emerged in 1939 and in the Scandinavian countries after the 
World War II; shortly after that, the beveridgean model appears in the UK. Outside of Europe, Japan 
adopted health coverage in 1922, with universal extension in 1946; Chile was the first developing country 
to create a statutory health system, in 1924, only for industrial workers at first, but also covering the more 
underprivileged population 28 years later, with the creation of Servicio Nacional de Salud. The sub-
Saharan African countries developed health insurances, albeit with several limitations, in the end of the 
sixties and seventies. In the end of the 70’s, more than 85 countries had established social security 
programs that included access to health care – more than a half were developing countries (Roemer 
1997). 
Despite the initial multiplicity of health schemes, over the years one can see a convergence of the 
various health policies towards the Bismarck and Beveridge models, which is still taking place. Actually, 
as the poorest countries’ economies are growing and citizens demand more from their governments, there 
is a growing interest from the latter in the redesigning of the social security programs, which include 
health coverage (Kruk 2013). If we take a look at the post-Soviet transition, we realize that the majority 
of the countries of the Eastern Bloc, including Soviet Union and allied countries from the eastern and 
central Europe – initially adopting the Soviet-type Semashko health model -, decided to enter a market-
oriented economy and to abandon the policlinics model, shifting towards a bismarckian, beveridgean or 
mixed model (Antoun et al. 2011; Lember 2002). Furthermore, the demographic inversion has forced 
countries to rethink their health models, not only those like China in which the universality is clearly not 
granted and urge for a transition to a bismarckian/beveridgean model, but also the countries that have 
established these models several decades ago (Joel and Dufour-Kippelen 2002; Liu and Sun 2015). 
Health reforms in the different countries have tried to find an equilibrium between a triad of 
factors: equity of access, efficiency and cost control (Or et al. 2010). For this reason we can understand 
the proliferation of the Bismarck and Beveridge models, precisely because they are the ones that better 
allow that equilibrium. However, there is no evidence that any of them has completely achieved it to date, 
because each one has their advantages and disadvantages. The beveridgean model has been recognized 
for lowering access inequality (because it is a universal model that avoids adverse selection), also 
permitting a better cost control as it is centrally managed (despite the risk of underfunding); the main 
disadvantages that have been reported are the lower ability to choose that is offered to users (by the 
gatekeeping process) and the long waiting times; on the other hand, the biggest virtue of the bismarckian 
model is the plenty of choice, even though it does not score so well in cost control (Bevan et al. 2010; Or 
et al. 2010; van der Zee and Kroneman 2007). 
Given the dominance of these two models, it would be interesting to see how they compare in a 
series of health indicators. To help us with this exercise, changes in information technology and 
associated advances in measurement methodology in the last decade made a lot easier and cheaper to 
collect and process information, and several countries have developed national repositories of health 
information or national performance assessment programmes (Papanicolas 2013). One can easily access 
data from the OECD, the European Commission, the Commonwealth Fund or the World Health 
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Organisation (WHO), although the comparative performance assessment initiatives are still in its earliest 
stages, with many challenges still existing in the implementation of comparative schemes, as discussed by 
Irene Papanicolas and Peter Smith in their work of 2013 for the European Observatory on Health Systems 
and Policies (Papanicolas 2013). 
Over the last years, some authors have tried to address this comparison between the two models. 
Zee and Kroneman do it in 2007 (van der Zee and Kroneman 2007), using indicators from 17 countries 
featuring three aspects related to health – health outcomes, health expenditure and population satisfaction. 
For such, they resorted to the OECD health data base 2006 and WHO health for all database 2006 and to 
the Eurobarometer studies from 1996, 1997 and 1999. As mentioned in the introduction of their work, 
few times this subject has been addressed until then, except for a work of Javier Elola (that used, in 1996, 
data of 1992 to similar indicators and did not find any differences in the health outcomes between the two 
models, but concluded that the beveridgean model allowed for better cost control and the bismarckian 
model for better population satisfaction) and for a chapter of the Saltman and Figueras’ book (that 
compared the two models in 2004 for a panoply of health outcomes indicators, not inferring the 
superiority of any model – they say it depends on the assessed parameter-, further concluding that the 
bismarckian model is slightly inferior in terms of “equity”, but superior in population satisfaction rates). 
In their work, Zee and Kroneman try to understand how the indicators behave over several years, and 
their results show that overall mortality rates and life expectancy have been performing better in the 
Bismarck model after 1980, and that for infant mortality the rates converged between the two types of 
systems, existing no differences since that year. In line with the previous studies, they conclude that 
population satisfaction rates are higher in the bismarckian model, but the latter is more expensive, while 
the beveridgean model allows for better cost control. In 2010, Or, Z et all have investigated the matter too 
(Or et al. 2010), using a pool of 5 countries (Denmark, England, France, Germany and Sweden). The 
authors analyse the health systems’ performance and try to explore possible key parameters of these 
systems that may explain the findings. Furthermore, they reflect about the recent reforms in those 
countries that try to attenuate the weaknesses of the health models – these include the introduction of a 
soft gatekeeping in France and Germany, an extension of the guarantees related to waiting times in 
Denmark and Sweden, and increased choice of providers in England. Their results for health performance 
match the previous studies, but introduce a new element based on the Eurobarometer results: the 
affordability, i.e., how easy it is for users to support health access costs, is lower in the bismarckian 
model. As reflected by Albert Weale in his commentary on the work of Zeynep Or et al, it seems that 
“there is a list of objectives that all systems might be thought to pursue, but in practice, given 
organisational constraints, some will score well on some values, whereas others will score well in 
different terms" (Weale 2015). 
Despite the attempt to implement the aforementioned reforms, these do not seem to have had 
much impact; in France and Germany, the bigger influence of the specialists has impeded the shift to a 
scenario where GPs take responsibility for a possible gatekeeping process; in the countries that follow the 
Beveridge model, the reforms have not reached the desirable outcomes too, except for Denmark that 
successfully lowered waiting times (Or et al. 2010). 
More than trying to find differences between the two models, it is important to understand the 
context of each country, and if there are any other factors that may influence the health outcomes. Thus, 
this work tries to answer four questions: (1) is the trend of the recent studies maintained? (2) What 
happens when we adjust these results to the economic strength of the populations (GDP per capita)? (3) 
Are there any differences in health outcomes that are explained by the economic strength of each 
country’s populations rather than by the adopted health model? (4) Have countries with the same health 
model different health outcomes according to the economic strength of their populations? 
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Methods 
Countries 
This study uses data from OECD countries, which were divided in two categories: one including 
those countries with a health system closer to the classic beveridgean type (type A), in which the financier 
and the provider are the same; other including bismarckian-like systems or those in which the financier is 
not the exclusive (or almost exclusive) provider, including the cases of compulsory public health 
insurance (type B) (table 1). Only countries in which health system has a non-private financing above 
90% were considered, in order to ensure that there is a good representativeness of a given model. With 
the aim of studying the effect of each country's wealth on health outcomes, all OECD countries were 
categorized according to their GDP per capita (table 2) and its effect on health outcomes was studied. In 
order to study the effect of the economic capacity of each country on the health outcomes of the countries 
of the initially defined categories, the first analysis was repeated for type A and type B countries, 
according to the median of GDP per capita in each group (table 3). 
All tables and figures can be accessed in Appendix. 
Data source 
Both health and economic indicators (GDP per capita) come from the OECD databases available 
in the context of the "Health at a Glance 2015 - OECD Indicators" report(OECD 2015). 
Indicators 
The selected indicators try to better reflect the following parameters: (1) health expenditure, (2) 
resources and productivity, (3) access to care, (4) population outcomes, (5) prevention and (6) long-term 
care. For health expenditure, the indicators of public health expenditure (per capita and as a percentage of 
GDP), the public share of expenditure on pharmaceuticals, and the percentage of private out-of-pocket 
expenditure on pharmaceuticals were used. With regard to resources and productivity, the indicators used 
were the consultations per doctor/year (medical productivity), permillage of hospital beds, nurses and 
magnetic resonance (MR) and computed tomography (CT) scans. To assess access to care, the percentage 
of unmet needs for medical care and medical consultations per person/year were used. With regard to 
population outcomes, life expectancy at birth, permillage of infant mortality, life expectancy and healthy 
life expectancy at age 65 (and the main determinants of the average life expectancy – mortality due to 
ischaemic heart disease and to cerebrovascular disease) and the percentage of perceived health status as 
good or very good (in population aged 15 years and over and in those aged 65 years and over) were 
chosen. To study the results in prevention, we analysed the percentage of DTP (diphtheria, tetanus, 
pertussis), measles and hepatitis B vaccination in children aged 1, the percentage of influenza vaccination 
for individuals aged 65 years and over, and the rates of breast (by mammogram between 50 and 69 years) 
and cervical cancer screening (by Pap smear between 20 and 69 years). For long-term care (LTC), the 
following indicators were used: public expenditure on LTC (as a percentage of GDP), permillage of beds 
for LTC for people aged 65 years and over and percentage of the population under LTC. 
 All numerical variables are presented as mean ± standard deviation, with expenditure values 
presented in US dollars (USD). All GDP values presented are GDP at purchasing power parity (PPP). The 
majority of the indicators refer to the year 2013 and the most recent data were used in all other cases.  
 According to the OECD report, data on the percentage of unmet needs for medical care come 
from two main sources: the European EU-SILC survey (2013), which questioned respondents whether 
there was any moment in the last 12 months when they felt they needed a medical evaluation but did not 
receive it, followed by a question about the reason for such occurrence (cases due to economic costs, 
waiting times and travel distance were covered); the second source is the Commonwealth Fund 
International Health Policy Survey (2013), which was conducted in 11 countries and asked respondents 
whether they did not visit the doctor when they had a medical problem, did not have a medical test, 
treatment or follow-up that was recommended by the doctor, or did not fill prescription for medicines or 
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skipped doses due to economic costs in the last year. Similar questions were also asked in the national 
survey in the Czech Republic in 2010, and these data were also used. 
Statistical analysis 
Statistical analysis of the data was done using the IBM SPSS Statistics 24 software. The Mann-
Whitney U test was used to compare numerical variables between two categories and the Kruskal-Wallis 
H to compare between more than two categories. A logistic regression was used to adjust results to GDP 
per capita. All the differences found were considered statistically significant when p ≤0.05. 
Results 
Health expenditure 
Public health expenditure (both per capita and as a percentage of GDP) is similar in type A and 
type B models (2953,2±974,8 vs 2567,4±1132,1; p=0,49 and 7,13±1,12 vs 6,57±1,69; p=0,32, 
respectively). The public share of expenditure on pharmaceuticals is higher in the type B model, although 
this result has no statistical significance (51,18±8,14 vs 60,87±14,68; p= 0,08); on the other hand, the 
percentage of private out-of-pocket expenditure on pharmaceuticals is higher in type A model 
(46,40±8,08 vs 33,05±13,67; p<0,02). The adjustment to GDP per capita does not affect the statistical 
significance of the results (see table 4). 
However, when assessing health expenditure by grouping countries according to their economic 
capacity, one can see that there is a directly proportional relationship between the GDP per capita and 
public health expenditure, both per capita and as a percentage of GDP (figure 1). Both the public share of 
expenditure on pharmaceuticals and the percentage of private out-of-pocket expenditure on 
pharmaceuticals do not appear to be affected by the country's economic capacity - there are no data for 
the first quartile in both cases (Figure 1). 
Within type A model, although public health expenditure, as a percentage of GDP, is similar 
between countries with higher and lower economic capacity (6,76±0,61 vs 7,45±1,39; p=0,43), when we 
look at public health expenditure per capita, it is higher in countries with GDP per capita above the 
median (2295,7±428,1 vs 3501,1±980,4; p=0,05). Both the public share of expenditure on 
pharmaceuticals and the percentage of private out-of-pocket expenditure on pharmaceuticals are not 
affected by the economic capacity of each country within type A model (57,64±4,26 vs 48,60±8,11; 
p=0,19 and 39,08±10,00 vs 49,33±5,96; p=0,19). In countries with type B model, the behaviour of these 
indicators is similar between those with GDP per capita above the median and those with GDP per capita 
equal to or below the median (see table 5). 
Resources and productivity 
Medical productivity (consultations per doctor/year) is consistently higher in type B model 
(1377,5±417,6; p<0,001); the hospital bed rate also scores better in this model (3,24±0,65 vs 6,31±2,70; 
p<0,01). The rate of nurses and MRI and CT scans does not appear to be affected by the model 
(11,05±4,28 vs 8,90±3,49; p=0,19; 47,94±21,48 vs 48,33±21,22; p=0,98 and 102,64±51,08 vs 
121,15±48,23; p =0,53, respectively). The adjustment to GDP per capita does not affect the statistical 
significance of the results (see table 4).  
Medical productivity is lower in richer countries; in fact, countries belonging to the last quartile 
are the ones with the lowest number of consultations per doctor/year, although there are no data from the 
first quartile (figure 2). The rate of nurses increases with the increase in the economic capacity of the 
countries analysed, while the difference between the rate of hospital beds is mainly observed between the 
poorest countries (first quartile) and the remaining (figure 2). The rate of magnetic resonance imaging and 
CT scans seems to be independent of the economic capacity of the countries, although there are no data 
for the first quartile (figure 2). 
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Among countries with type A model, medical productivity seems to be higher in the poorer 
countries, although this difference is not statistically significant (1702,5±260,0 vs 1160,8±364,0; p=0,07). 
The rate of nurses is higher in richer countries (7,10±1,96 vs 14,34±2,22; p=0,004), while rates for 
hospital beds, MRI scans, and CT scans appear to be similar between the two groups (3,06±0,33 vs 
3,39±0,84; p=0,79; 46,60±20,71 vs 48,95±25,17; p=0,86 and 104,23±33,29 vs 101,45±66,90; p=0,99). 
Again, the results between richer countries and poorer countries, within type B model, point in the same 
direction; in this case, the difference in medical productivity has statistical significance (see table 5). 
Access to care 
The percentage of unmet needs for medical care is similar between the two models (2,84±1,88 vs 
2,68±2,99; p=0,35), which becomes even more evident after adjusting for GDP per capita (see table 4). In 
turn, the number of medical consultations per person/year is higher in type B model (1377,5±417,6 vs 
2833,5±1454,3; p<0,001). The adjustment to GDP per capita does not affect the statistical significance of 
the results (see table 4). 
As we look at countries with higher GDP per capita, the percentage of unmet needs for medical 
care decreases, as well as the number of medical consultations per person/year (there are no data for the 
first quartile in both cases) (figure 3). Within type A model, the abovementioned percentage does not 
appear to be affected by the economic capacity (3,13±2,80 vs 2,65±1,25; p=0,91), contrary to what 
happens in type B model (4,30±3,61 vs 1,07±0,62; p<0,02). In both type A and type B models, economic 
capacity does not seem to affect the number of medical consultations per person/year (5,4±1,6 vs 4,0±1,2; 
p=0,25 e 9,7±3,2 vs 6,9±1,7; p=0,17, respectively). 
Population outcomes 
Life expectancy at birth seems to be similar in both models (81,6±0,9 vs 80,7±2,2; p=0,58), 
while the infant mortality rate appears to be higher in type B model (2,71±0,87 vs 3,40±1,00; p=0,05), 
although this difference is not statistically significant, when adjusted to GDP per capita (see table 4). 
Although the life expectancy at age 65 practically does not present differences between the two models 
(20,0±0,6 vs 19,6±1,5; p=0,95), healthy life expectancy at age 65 is consistently higher in countries 
adopting type A model (11,3±2,6 vs 8,4±2,0; p<0,02). The mortality rate due to ischaemic heart disease 
and the mortality rate due to cerebral vascular disease are not affected by the adopted model 
(100,22±35,67 vs 119,18±99,93; p=0,61 e 60,26±11,72 vs 67,95±30,68; p=0,64, respectively), as well as 
the rates of perceived health status as good or very good, in individuals aged 15 years and over and in 
those aged 65 and over (72,65±11,35 vs 67,08±14,61; p=0,28 e 51,22±20,70 vs 39,90±20,07; p=0,20, 
respectively). Except for the infant mortality rate, the adjustment to GDP per capita does not affect the 
statistical significance of the results (see table 4). 
When countries are categorized according to quartiles of GDP per capita, one can see that all of 
the abovementioned indicators are influenced by countries' economic capacity (with the exception of 
ischaemic heart disease mortality), with richer countries scoring better (figure 4). Within the type A 
countries, the differences are found in the infant mortality rate and healthy life expectancy at age 65 
(although not statistically significant; 3,22±0,77 vs 2,28±0,75; p=0,08 e 9,2±1,3 vs 12,6±2,4; p=0,07, 
respectively), while type B countries show statistically significant differences between the poorer and 
richer countries (with the advantage of the latter) with regard to healthy life expectancy at age 65 (7,3±2,0 
vs 9,6±1,5; p=0,05) and the perception of good or very good health status (both in individuals aged 15 
years and over, and in individuals aged 65 and over; 59,71±14,68 vs 76,26±8,19; p=0,006 e 25,92±10,64 
vs 57,58±14,02; p<0,001, respectively) (see table 5). 
Prevention 
No differences were found between the two models regarding the DTP (95,45±2,42 vs 
96,44±4,03; p=0,07), measles (93,64±3,01 vs 94,72±5,43; p=0,13) and hepatitis B (92,00±8,99 vs 
91,79±8,73; p=0,66) vaccination rate, which became particularly evident after adjusting for GDP per 
capita (see table 4). Also, the influenza vaccination rate for individuals aged 65 years and over did not 
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present differences between the two models (51,74±15,26 vs 46,16±20,55; p=0,59). The screening rate 
for breast cancer by mammogram (between 50 and 69 years) is higher in type A model (72,91±7,68 vs 
59,99±13,72; p=0,01), while for the screening of cervical cancer, the difference found is not statistically 
significant (67,42±11,47 vs 60,75±12,80; p=0,16) (see table 4). 
The first-year vaccination rate (DTP, measles and hepatitis B) is substantially lower in countries 
belonging to the first quartile of GDP per capita, but appears to stabilize from the second quartile on; with 
regard to influenza vaccination, this stabilization occurs from the third quartile on (figure 5). The 
screening rate for breast and cervical cancers increases as we move to higher quartiles, although this 
difference is only statistically significant in the latter case (figure 5). Within type A, there appear to be no 
differences between the richest and poorest countries in relation to the prevention indicators mentioned 
above (see table 5). On the other hand, this difference is evident in the case of type B model, in which 
countries with lower GDP per capita have higher rates of vaccination in the first year - cases of measles 
and hepatitis B (96,70±3,23 vs 92,25±6,76; p<0,03); differences in the case of DTP vaccination have no 
statistical significance (97,90±1,85 vs 94,63±5,32; p=0,12). Even though influenza vaccination and breast 
cancer and uterine cancer screenings appear to be superior in richer countries, the differences found are 
not statistically significant (see table 5). 
Long-term care 
Respecting LTC, public expenditure as a percentage of GDP appears to be higher in type A 
model, although there is no statistical significance in this analysis (1,51±1,01 vs 0,93±0,72; p=0,29; 
p2=0,15), nor reflex of that hypothetical higher expenditure, in terms of the percentage of the population 
under LTC (2,18±1,36 vs 2,39±1,20; p=0,70) or the rate of beds for that purpose for the population aged 
65 and over (53,70±15,24 vs 51,65±13,83; p=0,86).  
When these indicators are assessed against GDP per capita, to the detriment of the adopted 
model, public expenditure on LTC increases with progression in quartiles, although this does not result in 
statistically significant differences in the percentage of the population under LTC or in the rate of beds for 
LTC for individuals aged 65 years and over (figure 6).  
The difference in public investment in LTC between rich and poor countries is particularly 
evident in type B model (0,50±0,40 vs 1,55±0,64; p=0,001), and no differences were found within type A 
model (0,41±0,36 vs 1,95±0,80; p=0,19); however, in none of the models are there differences in the 
other two parameters analysed for LTC (see table 5). 
Discussion 
Health expenditures 
The first goal of this work is to compare type A and type B models (with an adjustment to GDP 
per capita), trying to understand if the trend of the last comparative studies is maintained on one hand, 
and which differences can be found that have not been studied yet, on the other. Cost control has 
consistently been singled out as one of the strengths of the type A model, although this study does not 
demonstrate this; in fact, not only are there no statistically significant differences between the two models 
in terms of public health expenditure (both per capita and as a function of GDP), as the average of these 
expenses is even higher in the type A model. One possible explanation could be the awakening of a global 
financial and economic crisis, which has consistently suppressed the growth of public health expenditure 
in recent years and has eventually brought the countries of the two models closer together. 
Furthermore, Or Z. et al had come to the conclusion that the affordability reported by the 
populations was favourable to the Beveridge model, trying to draw a parallel with the out-of-pocket 
expenditure, which was higher in countries with the Bismarck model (except for Denmark, where this 
parallelism apparently cannot be done); although the present study does not use Eurobarometer data, one 
can observe that out-of-pocket expenditure on pharmaceuticals is significantly higher in type A model, 
which seems to go against previous results. This may have several explanations; first, it can be explained 
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by a methodological difference - in fact, this analysis is based on results from 29 countries, which 
significantly widens the sample, compared to the study by Or Z. et al; secondly, although the affordability 
is not a completely reliable indicator of the real difficulties in dealing with out-of-pocket payments, 
neither is the one used in this study - out-of-pocket payments differ fairly between countries (while most 
of these payments are actually intended for outpatient medicines in certain countries, such as Poland, the 
Czech Republic, Hungary or Canada, in other countries such as Luxembourg, Belgium or Switzerland, 
most of these payments are intended for curative care and, in Portugal, for copayments of medicines and 
especially for dental care). 
Resources and productivity 
Medical productivity is higher in type B model, which is much due to the fact that, in countries 
that adopt this model, there is a fee-for-service scheme, which is a strong incentive to produce 
consultations, in contrast to countries with type A, where a fixed wage independent of productivity is 
established. The explanation for the higher rate of hospital beds in type B model may be the greater profit 
associated with a greater number of hospitalizations. 
Access to care 
Regarding access to care, this study showed that access measured by the number of medical 
consultations per person/year scores significantly better in type B model; this may reflect the greater ease 
of access to specialties (historically recognized to the bismarckian model); despite this, there are no 
differences regarding the rates of unmet needs for medical care, which may point to a greater sensitivity 
on the part of the patients in these countries, fuelled by the aforementioned ease of access. 
Population outcomes 
Although Eurobarometer data are not used for population satisfaction, which is often recognized 
as being higher in the bismarckian model, the OECD report provides information on the percentage of the 
population that has a perception of their health status as good or very good, and this study does not find 
differences between the two models, in both age groups; despite this, it should be noted that there is a 
tendency (not statistically significant) for a better perception of health status in individuals aged 65 years 
and over in type A model, which may be related to another parameter analysed here which also scores 
better in this model - healthy life expectancy at age 65. On the other hand, and in line with what is stated 
in the OECD report itself, it is necessary to admit that these data is always dependent on the rigor with 
which the questions are asked and the answers obtained in the questionnaires carried out in the different 
countries, and on social and cultural factors; moreover, we might think that, because the older population 
generally reports worse health, a hypothetical predominance of countries with an older population in the 
type B model could influence the results; however, this does not seem to happen - in fact, although we 
have countries with a large percentage of the elderly population belonging to the type B model, such as 
Japan, South Korea or Germany, this also happens with type A model in countries such as Spain, Italy or 
Portugal; to support this reasoning, countries that follow the type B model, such as Israel or Australia, 
have the lowest rate of elderly population among the countries analysed (OECD 2015). 
There were no differences in life expectancy at birth, and these results do not completely 
coincide with those obtained by Zee and Kroneman, who pointed to superiority in the Bismarck model 
after 1980; nevertheless, in that study, the superiority was only of 0.5 years, and if we analyse those data 
carefully, we notice that in the last few years there was a slight period in which the Beveridge model was 
slightly superior, and both models are progressing for an increase in average life expectancy at almost the 
same rate; the most recent data from the present study again show the type A model, on average, slightly 
better, but without statistically significant differences; actually, this does not seem to be an indicator that 
differentiates the two models. With regard to infant mortality, the trend towards higher values in type B 
model may partly reflect different methods in registration practices for very premature infants; although 
the OECD report used a 22-week minimum threshold in most countries, this was not possible in certain 
countries such as Australia or Canada, which may have slightly overestimated the values on the type B 
model side. Furthermore, infant mortality in the more developed countries is greatly affected by at least 
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two factors: the rate of assisted reproduction and the ability to carry out at-risk pregnancies (often with 
preterm birth). Neonates, in these conditions, have a significantly higher risk of death in the early 
lifetimes. As child mortality rates in these countries are already at very low levels, any increase due to 
these conditions may be significant. 
Prevention 
In terms of prevention, the differences are mainly found for screening for breast (with statistical 
significance) and cervical cancer; this can be explained by the fact that, in countries that follow type A 
model, primary health care plays a greater role in the national health scheme, which may allow for a more 
effective follow-up; plus, some countries belonging to the type B model, such as Israel or Switzerland, do 
not have organized cervical cancer screening programs because of its low incidence. Despite the 
difference regarding breast cancer, it is expected that this gap will decrease over the next few years, as 
some countries with very low screening rates at the beginning of the century, such as a South Korea or a 
Slovak Republic (with a type B model), have been progressively increasing those rates, while countries 
where they were already high, such as Finland, Norway or Ireland (type A model), have been reducing 
them slightly, mainly due to recent concerns about false-positive results, over-diagnosis and over-
treatment (which even led WHO to re-evaluate  screening recommendations (WHO | WHO position paper 
on mammography screening  2014)). 
Long-term care 
With regard to the LTC, the health model does not seem to affect the investment in this area, 
which seems scarce in view of demographic trends in most countries. In fact, it can be expected that in 
either model this investment will increase, and type A countries seem to have some advantage (as can be 
seen from the non-statistically significant higher trend in terms of public expenditure on LTC, as a 
function of GDP); one may speculate whether the equity pillars of the beveridgean model may have some 
effect in this matter in the future, by attenuating the effect of adverse selection. 
Analysis as a function of economic capacity 
The results obtained when studying the indicators according to the economic capacity of the 
various countries allow us to draw some conclusions. In terms of health expenditure, it is possible to 
conclude not only that the richer a country is, the greater its expenditure in absolute terms (as would be 
expected), but also that a greater proportion of its wealth is devoted to health, what shows us the 
increased importance given to health in these countries; on the other hand, countries in the second and 
third quartiles have the best (sometimes almost the best) results in terms of medical productivity, 
population outcomes (life expectancy at birth, infant mortality, life expectancy at age 65 and healthy life 
expectancy ate age 65) and prevention by vaccination (DTP, measles and hepatitis B in the first year), 
being only surpassed by the fourth quartile countries in terms of access (medical consultations per 
person/year and rate of unmet needs for medical care), screening prevention (breast and cervical cancer) 
and investment in LTC, although not all of these latter results have statistical significance. From this we 
can conclude two things: first, it seems undeniable that a greater economic capacity is capable of ensuring 
better results, with the poorer countries having more difficulty competing with the rest; however, it is also 
interesting to note that there seems to be a point where economic capacity ceases to play such a 
preponderant role in health outcomes, and that this is somewhere between the second and third quartiles. 
Analysis as a function of economic capacity, per model 
Within type A model, there are practically no statistically significant differences between the 
poorest and richest countries; some indicators show a non-statistically significant trend that is in line with 
the results of analysis by quartiles of GDP per capita. In type B model, the same is true for public health 
expenditure per capita, although other differences are also evident; in fact, poorer countries seem to score 
significantly worse in terms of access (measured by unmet needs for medical care rate) and population 
outcomes (healthy life expectancy at age 65 and perceived health status as good or very good); some 
indicators score better in the poorer countries within type B model, such as medical productivity (which 
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shows a similar trend, though not statistically significant, in type A model) and prevention by vaccination 
(perhaps the appearance of movements that go against vaccination of children, associated with the greater 
"liberalism" of non-Beveridge systems, may have some influence in this matter). 
Conclusions 
The present study shows that, increasingly, an analysis based on the typology of the health model 
per se becomes less relevant if other important variables, such as the economic capacity of each country, 
are not taken into account. In fact, the different models seem to converge more than ever and the 
differences found in a simple analysis are more difficult to find. Among these, medical productivity and 
ease of access to health care seem to be the most evident, and are favourable to type B model (non-
beveridgean). However, it is also in this model that the poorest countries have worse results, so that they 
will be able to more easily amortize social differences in relation to the richer countries in type A model. 
Health outcomes, in turn, are influenced much more clearly by the economic capacity of each 
country than by the adopted model, and this study showed that there appears to be a certain amount of 
GDP per capita, between the second and third quartiles, which ensures the best results, and that an 
additional increase in GDP per capita does not offer much additional benefit. 
Study limitations 
Some limitations of this study deserve to be emphasized, namely the fact that it uses indicators 
referring to a point in time; in fact, most of the indicators refer specifically to the year 2013, while in 
others the information for that year does not exist and the most recent available data have been used. 
Also, data from certain countries are missing when it comes to certain indicators, mainly regarding the 
poorest belonging to the first quartile of GDP per capita. This fact has reduced the power of the statistical 
analysis performed. 
On the other hand, the indicators that appeared most relevant within those available in the OECD 
report were chosen, but others could have been used; although many of the indicators used by this work 
are identified as areas of concern for comparison in the Health System Performance Comparison report 
for the European Observatory on Health Systems and Policies, other areas have not been addressed, 
including morbidity, avoidable mortality, population risk factors or respect for the dignity of the patient 
(Papanicolas 2013). When developing such a study, it is important to notice that one should establish a 
limit of parameters to be analysed and that if, on the one hand, a greater number of indicators allows a 
more comprehensive and realistic view of the various factors that influence a given health system, on the 
other, that makes it difficult to identify specific areas for action and implementation of short-term 
reforms. 
Another aspect that should be highlighted is the analysis carried out according to GDP per capita 
– although the results of this study attribute a central role to this variable in population health outcomes, 
the truth is that other factors that were not addressed, such as the architecture of health systems in some 
countries or access to the "state of the art", can have an influence on the analysed parameters (although 
these factors are in some way interconnected with the economic capacity of a population). 
Therefore, it should be noted that although it is desirable to draw conclusions from such studies 
and to make generalizations, it must be borne in mind that there are still several obstacles to these 
comparative schemes, not only in the collection of information (mainly the most subjective, concerning 
the well-being and dignity of individuals), but also in the interpretation of this information (and the value 
it can add). 
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Appendix 
Type A Type B 
Denmark 
Finland 
Iceland 
Ireland 
Italy 
Norway 
New Zealand 
Portugal 
Spain 
Sweden 
United Kingdom 
 
Australia 
Austria 
Belgium 
Canada 
Czech Republic 
France 
Germany 
Greece 
Hungary 
Israel 
Japan 
Luxembourg 
Netherlands 
Poland 
Slovak Republic 
Slovenia 
South Korea 
Switzerland 
Table 1 – Countries distribution per model 
1st Quartile 2nd Quartile 3rd Quartile 4th Quartile 
Brazil 
Chile 
China 
Colombia 
Costa Rica 
India 
Indonesia 
Latvia 
Mexico 
South Africa 
Turkey 
Czech Republic 
Estonia 
Greece 
Hungary 
Israel 
Lithuania 
Poland 
Portugal 
Russian Federation 
Slovak Republic 
Slovenia 
Belgium 
Canada 
Finland 
France 
Iceland 
Italy 
Japan 
New Zealand 
South Korea 
Spain 
United Kingdom 
Australia 
Austria 
Denmark 
Germany 
Ireland 
Luxembourg 
Netherlands 
Norway 
Sweden 
Switzerland 
United States 
Table 2 – Countries distribution in quartiles, per GDP per capita  
Type A Type B 
> median ≤ median > median ≤ median 
Denmark 
Finland 
Iceland 
Ireland 
Norway 
Sweden 
Italy 
New Zealand 
Portugal 
Spain 
United Kingdom 
Australia 
Austria 
Belgium 
Canada 
Germany 
Luxembourg 
Netherlands 
Switzerland 
Czech Republic 
France 
Greece 
Hungary 
Israel 
Japan 
Poland 
Slovak Republic 
Slovenia 
South Korea 
Table 3 – Countries distribution as a function of GDP per capita, per model 
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Indicator Type A Type B P P2 
Health expenditure     
Public health expenditure (per capita) 2953,2±974,8 2567,4±1132,1 0,49 0,30 
Public health expenditure (as a % of GDP) 7,13±1,12 6,57±1,69 0,32 0,34 
Public share of expenditure on pharmaceuticals (%) 51,18±8,14 60,87±14,68 0,08 0,07 
Private out-of-pocket expenditure on pharmaceuticals (%) 46,40±8,08 33,05±13,67 <0,02 <0,03 
Resources and productivity     
Medical productivity (consultations per doctor/year) 1377,5±417,6 2833,5±1454,3 <0,001 <0,03 
Nurses (‰) 11,05±4,28 8,90±3,49 0,19 0,12 
Hospital beds (‰) 3,24±0,65 6,31±2,70 <0,01 0,01 
MR scans (‰) 47,94±21,48 48,33±21,22 0,98 0,99 
CT scans (‰) 102,64±51,08 121,15±48,23 0,53 0,40 
Access to care     
Medical consultations per person/year 4,66±1,53 8,41±2,90 <0,001 <0,02 
Unmet needs for medical care (%) 2,84±1,88 2,68±2,99 0,35 0,83 
Population outcomes     
Life expectancy at birth (years) 81,6±0,9 80,7±2,2 0,58 0,19 
Infant mortality (‰) 2,71±0,87 3,40±1,00 <0,05 0,08 
Life expectancy at age 65 (years) 20,0±0,6 19,6±1,5 0,95 0,40 
Healthy life expectancy at age 65 (years) 11,3±2,6 8,4±2,0 <0,02 0,02 
Perceived health status as good or very good (% of population 
aged 15 years and over) 
72,65±11,35 67,08±14,61 0,28 0,30 
Perceived health status as good or very good (% of population 
aged 65 years and over) 
51,22±20,70 39,90±20,07 0,20 0,15 
Mortality due to ischaemic heart disease (per 100 000) 100,22±35,67 119,18±99,93 0,61 0,58 
Mortality due to cerebrovascular disease (per 100 000) 60,26±11,72 67,95±30,68 0,64 0,43 
Prevention     
DTP (diphtheria, tetanus, pertussis) (% of children aged 1) 95,45±2,42 96,44±4,03 0,07 0,48 
Measles vaccination in the first year (% of children aged 1) 93,64±3,01 94,72±5,43 0,13 0,58 
Hepatitis B vaccination (% of children aged 1) 92,00±8,99 91,79±8,73 0,66 0,89 
Influenza vaccination (% of population aged 65 and over) 51,74±15,26 46,16±20,55 0,59 0,46 
Mammography screening (% of women aged 50-69) 72,91±7,68 59,99±13,72 0,01 0,02 
Cervical cancer screening (% of women aged 20-69) 67,42±11,47 60,75±12,80 0,16 0,18 
Long-term care     
Public expenditure on long-term care (as a % of GDP) 1,51±1,01 0,93±0,72 0,29 0,15 
Beds for long-term care (per 1000 people aged 65 years and 
over) 
53,70±15,24 51,65±13,83 0,86 0,79 
Population under long-term care (%) 2,18±1,36 2,39±1,20 0,70 0,62 
Table 4 – Comparison between type A model and type B model in the various indicators analysed (P), with subsequent adjustment to GDP per capita (P2). 
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Indicator Type A Type B 
≤ median > median P ≤ median > median P 
Health expenditure       
Public health expenditure (per 
capita) 
2295,7±428,1 3501,1±980,4 0,05 1778,6±768,6 3553,4±594,3 0,001 
Public health expenditure (as a % 
of GDP) 
6,76±0,61 7,45±1,39 0,43 5,85±1,63 7,46±1,35 0,10 
Public share of expenditure on 
pharmaceuticals (%) 
57,64±4,26 48,60±8,11 0,19 57,09±13,60 65,13±15,56 0,28 
Private out-of-pocket expenditure 
on pharmaceuticals (%) 
39,08±10,00 49,33±5,96 0,19 36,75±14,75 28,90±11,87 0,32 
Resources and productivity       
Medical productivity 
(consultations per doctor/year) 
1702,5±260,0 1160,8±364,0 0,07 3513,6±1653,9 2068,3±666,2 <0,04 
Nurses (‰) 7,10±1,96 14,34±2,22 0,004 6,74±2,21 11,60±2,88 0,001 
Hospital beds (‰) 3,06±0,33 3,39±0,84 0,79 6,89±3,05 5,48±2,03 0,42 
MR scans (‰) 46,60±20,71 48,95±25,17 0,86 44,51±22,04 52,63±20,83 0,37 
CT scans (‰) 104,23±33,29 101,45±66,90 0,99 120,17±49,91 122,26±49,67 0,99 
Access to care       
Medical consultations per 
person/year 
5,4±1,6 4,0±1,2 0,25 9,7±3,2 6,9±1,7 0,17 
Unmet needs for medical care (%) 3,13±2,80 2,65±1,25 0,91 4,30±3,61 1,07±0,62 <0,02 
Population outcomes       
Life expectancy at birth (years) 81,9±1,1 81,4±0,7 0,66 79,9±2,8 81,6±0,7 0,36 
Infant mortality (‰) 3,22±0,77 2,28±0,75 0,08 3,35±1,22 3,46±0,70 0,76 
Life expectancy at age 65 (years) 20,3±0,7 19,73±0,40 0,25 19,1±1,9 20,1±0,5 0,32 
Healthy life expectancy at age 65 
(years) 
9,2±1,3 12,6±2,4 0,07 7,3±2,0 9,6±1,5 0,05 
Perceived health status as good or 
very good (% of population aged 
15 years and over) 
69,42±15,70 75,33±6,45 0,43 59,71±14,68 76,26±8,19 0,006 
Perceived health status as good or 
very good (% of population aged 
65 years and over) 
43,91±28,59 57,32±10,24 0,25 25,92±10,64 57,58±14,02 <0,001 
Mortality due to ischaemic heart 
disease (per 100 000) 
85,20±35,34 112,75±33,65 0,33 143,68±129,14 88,56±29,72 0,97 
Mortality due to cerebrovascular 
disease (per 100 000) 
63,90±16,53 57,23±5,64 0,54 84,80±32,23 46,89±6,12 0,01 
Prevention       
DTP (diphtheria, tetanus, 
pertussis) (% of children aged 1) 
95,80±2,28 95,17±2,71 0,79 97,90±1,85 94,63±5,32 0,12 
Measles vaccination in the first 
year (% of children aged 1) 
94,00±3,08 93,33±3,20 0,79 96,70±3,23 92,25±6,76 <0,03 
Hepatitis B vaccination (% of 
children aged 1) 
95,75±2,22 84,50±14,85 0,28 94,57±9,13 89,00±7,98 0,05 
Influenza vaccination (% of 
population aged 65 and over) 
61,00±10,78 42,48±13,90 0,06 38,14±22,34 56,19±13,33 0,10 
Mammography screening (% of 
women aged 50-69) 
72,20±5,91 73,61±9,83 0,84 55,73±13,85 65,31±12,32 0,17 
Cervical cancer screening (% of 
women aged 20-69) 
63,82±15,59 70,42±6,71 0,79 57,10±14,14 64,86±10,48 0,17 
Long-term care       
Public expenditure on long-term 
care (as a % of GDP) 
0,41±0,36 1,95±0,80 0,19 0,50±0,40 1,55±0,64 0,001 
Beds for long-term care (per 1000 
people aged 65 years and over) 
43,61±17,06 60,42±10,39 0,11 45,55±14,94 58,53±8,93 0,20 
Population under long-term care 
(%) 
1,73±1,04 2,48±1,56 0,35 2,20±1,06 2,59±1,37 0,80 
Table 5 – Comparison between countries with GDP per capita ≤ median and GDP per capita > median, per model. 
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Figure 1 – (A) Public health expenditure per capita (p<0,001), (B) public health expenditure as a percentage of GDP (p<0,001), (C) public share of expenditure on 
pharmaceuticals (%) (p=0,63) and (D) private out-of-pocket expenditure on pharmaceuticals (%) (p=0,53), as a function of GDP per capita.  
*No data for the first quartile. 
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Figure 2 – (A) Medical productivity (number of consultations per doctor/year) (p<0,02), and permillage of (B) nurses (p<0,001), (C) hospital beds (p=0,001), (D) 
magnetic resonance scans (p=0,22) and (E) computed tomography scans (p=0,72), as a function of GDP per capita. 
*No data for the first quartile. 
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Figure 3 – (A) Medical consultations per person/year (p=0,07) and (B) percentage of unmet needs for medical care (p=0,02), as a function of GDP per capita. 
*No data for the first quartile. 
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Figure 4 – (A) Life expectancy at birth (p<0,001), (B) permillage of infant mortality (p<0,001), (C) life expectancy at age 65 (p<0,001), (D) healthy life 
expectancy at age 65 (p=0,007), percentage of individuals aged (E) 15 years and over or (F) 65 years and over that perceive their health status as good or very 
good (p<0,02 e p<0,001, respectively) and mortality, per 100 000, due to (G) ischaemic heart disease (p=0,21) and to (H) cerebrovascular disease (p=0,002), as a 
function of GDP per capita. 
*No data for the first quartile. 
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Figure 5 – Percentage of (A) DTP (diphtheria, tetanus, pertussis), (B) measles and (C) hepatitis B vaccination in children aged 1 (p=0,03, p=0,02 e p <0,05, 
respectively), (D) percentage of influenza vaccination in individuals aged 65 and over (p=0,005), percentage of (E) mammography screening in women aged 50-69 
and of (F) cervical cancer screening in women aged 20-69 (p=0,12 and p=0,04, respectively), as a function of GDP per capita. 
*No data for the first quartile. 
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Figure 6 – (A) Public expenditure on LTC, as a percentage of GDP (p<0,001), (B) hospital beds for LTC, per 1000 individuals aged 65 years and over (p=0,26) 
and (C) percentage of population under LTC (p=0,17), as a function of GDP per capita. 
*No data for the first quartile.
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